Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: Results of a prospective randomized multicenter trial - 29/08/11
Abstract |
Background: Photodynamic therapy (PDT) is a promising new treatment modality for actinic keratoses. Methyl aminolevulinate (MAL) (Metvix, PhotoCure, Oslo, Norway) leads to selective accumulation of photoactive porphyrins in premalignant skin lesions and makes the lesions susceptible to phototoxic effects on illumination with red light. Objective: This multicenter, randomized, double-blind study compared complete response rates, cosmetic outcome, and patient satisfaction for PDT with cream containing 160 mg/g MAL or placebo cream in the treatment of actinic keratoses. Methods: After application of the cream under occlusion for 3 hours, the lesions were illuminated by noncoherent red light (570-670 nm, light dose 75 J/cm2). Treatment was repeated after 1 week and response was assessed 3 months later. A total of 80 patients were randomized into the study, 42 in the active and 38 in the placebo group. Results: Complete lesion response rate was higher after MAL PDT than placebo, 89% versus 38% per protocol analysis (P = .001). An excellent or good cosmetic outcome was reported in more than 90% of patients treated with MAL. Conclusion: In this small study, PDT using topical MAL was a safe and effective treatment for actinic keratoses with excellent cosmetic outcome. It is a promising treatment that could benefit from further study. (J Am Acad Dermatol 2003;48:227-32.)
Le texte complet de cet article est disponible en PDF.Plan
Funding source: A grant from PhotoCure ASA, Oslo, Norway. |
|
Conflict of interest: None identified. |
|
Reprints not available from authors. |
|
0190-9622/2003/$30.00 + 0 |
Vol 48 - N° 2
P. 227-232 - février 2003 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?